Section Arrow
HALO.NASDAQ
- Halozyme Therapeutics
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 64.48
+0.66 (+1.03%)
Day High 
64.61 
Prev. Close
63.82 
1-M High
66 
Volume 
830.09K 
Bid
62.91
Ask
65.93
Day Low
63.38 
Open
63.79 
1-M Low
56.9 
Market Cap 
7.88B 
Currency USD 
P/E 18.61 
%Yield -- 
10-SMA 63.53 
20-SMA 61.63 
50-SMA 58.7 
52-W High 66 
52-W Low 37.73 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.43/7.14
Enterprise Value
9.39B
Balance Sheet
Book Value Per Share
2.95
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
1.02B
Operating Revenue Per Share
6.32
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.